BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
News|Articles|April 9, 2019
Catalent Expands HME Capabilities
Author(s)Pharmaceutical Technology Editors
Catalent invests $5 million in hot melt extrusion capabilities at Somerset, NJ facility.
Advertisement
Catalent Pharma Solutions announced plans to expand its OptiMelt hot melt extrusion (HME) capabilities at the company’s Somerset, NJ, drug development center with a $5-million investment. The investment, announced in an April 4, 2019 press statement, will include the addition of manufacturing and analytical equipment for preclinical and early clinical phase development and downstream processing technologies to support HME formulations.
In 2018, Catalent announced an investment in the Somerset facility to create a drug development center of excellence, which, along with sites in San Diego, CA and Nottingham, UK, offers formulation and development services for preclinical to clinical Phase 2b formulation, analytical, and manufacturing solutions for orally delivered small molecules.
Catalent’s 265,000-sq.-ft headquarters and development center in Somerset houses analytical labs and pilot- and clinical-scale equipment including hot melt extrusion and fluid-bed processing. The facility has expertise in handling potent and US Drug Enforcement Administration compounds for capsules, tablets, minitablets, and multi-particulates.
Source:
Advertisement
Related to this article
Univar Solutions scientists developed a lidocaine cream built on starch, sorbitol, coconut oil, and beeswax that matched a commercial benchmark on viscosity, assay, and hydration.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.
FDA final guidance defines when companion app output counts as drug labeling and when device-connected or standalone apps belong in prescribing information.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Formulation and Evaluation of a Sustainable Analgesic Cream Utilizing Renewable Bio-Based Ingredients and Green Chemistry Design Principles
2
Nitrosamine Problems and Industry Solutions: PharmTech Explained
3
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
4
Germany’s Medical Biotechnology Sector is Flourishing
5